Plasmodium falciparum reticulocyte-binding protein homolog 5 (RH5) is a unique asexual blood-stage malaria vaccine candidate because of its high conservation and essential biological function of binding to basigin on the erythrocyte surface. Recent studies by Barrett et al., Wang et al., and King et al., have brought RH5-based vaccine development a step forward based on a rational antigen design strategy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pt.2024.09.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Human migrations, anthropogenic changes, and insect-borne diseases in Latin America.
Parasit Vectors
January 2025
Department of Agriculture, Food and Environment, University of Pisa, Pisa, Italy.
Rapid urbanization and migration in Latin America have intensified exposure to insect-borne diseases. Malaria, Chagas disease, yellow fever, and leishmaniasis have historically afflicted the region, while dengue, chikungunya, and Zika have been described and expanded more recently. The increased presence of synanthropic vector species and spread into previously unaffected areas due to urbanization and climate warming have intensified pathogen transmission risks.
View Article and Find Full Text PDFEmerging nanotechnology-driven drug delivery solutions for malaria: Addressing drug resistance and improving therapeutic success.
Int J Pharm
January 2025
Centre for Transgenic Plant Development, Department of Biotechnology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi 110062, India. Electronic address:
Malaria remains the fifth deadliest parasitic infection worldwide, despite significant advancements in technology. A major challenge in combating this disease lies in the growing resistance of malaria parasites to antimalarial drugs and insect vectors to insecticides. The emerging inefficacy of artemisinin-based combination therapies (ACTs) further exacerbates the issue.
View Article and Find Full Text PDFDistinct immunogenicity outcomes of DNA vaccines encoding malaria transmission-blocking vaccine target antigens Pfs230D1M and Pvs230D1.
Vaccine
January 2025
Department of Global Health, George Washington University, Washington, D.C., USA. Electronic address:
Transmission-blocking vaccines (TBVs) targeting sexual-stage antigens represent a critical tool for malaria control and elimination through inhibiting parasite development within mosquitoes. P230, displayed on the surface of gametocytes and gametes, plays a crucial role in gamete fertilization and is one of the leading TBV candidates for both Plasmodium falciparum and P. vivax.
View Article and Find Full Text PDFThe clinical range and management of spontaneous rupture of the pathological malarial spleen (SRPMS): A short case series from Sudan.
Int J Surg Case Rep
January 2025
Faculty of Medicine and Health Sciences, Omdurman Islamic University, Sudan.
Introduction: Spontaneous rupture of the pathological malarial spleen (SRPMS) is a rare condition with a mortality rate among travelers of approximately 38 %, whereas it was around 10 % for local citizens. The mortality rate for overwhelming post-splenectomy sepsis was reported to be about 50 %.
Methods: A retrospective study was conducted from febraury2022 to July 2022.
Plasmodium falciparum surf4.1 in clinical isolates: From genetic variation and variant diversity to in silico design immunopeptides for vaccine development.
PLoS One
January 2025
Department of Parasitology and Entomology, Faculty of Public Health, Mahidol University, Bangkok, Thailand.
SURFINs protein family expressed on surface of both infected red blood cell and merozoite surface making them as interesting vaccine candidate for erythrocytic stage of malaria infection. In this study, we analyze genetic variation of Pfsurf4.1 gene, copy number variation, and frequency of SURFIN4.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!